Sugi Predict

Sugi Predict / Compounds / SCHEMBL715409

SCHEMBL715409

SCHEMBL715409

CC(N)(C(=O)O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 3/20 0.59
▸ CYP2C19 P33261 1/20 0.59
▸ CES2 O00748 1/20 0.50
▸ CYP2D6 P10635 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ MEN1 O00255 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ SRD5A2 P31213 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ HTR3E A5X5Y0 1/20 0.46
▸ HTR3B O95264 1/20 0.46
▸ HTR3A P46098 1/20 0.46
▸ HTR3D Q70Z44 1/20 0.46
▸ HTR3C Q8WXA8 1/20 0.46
▸ MGLL Q99685 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL382497 1.00 CYP1A2 (0.59) CYP1A2CYP2C19CES2CYP2D6PKM
SCHEMBL717446 1.00 CYP1A2 (0.59) CYP1A2CYP2C19CES2CYP2D6PKM
SCHEMBL30605754 1.00 CYP1A2 (0.59) CYP1A2CYP2C19CES2CYP2D6PKM
Hydrochloric Acid SCHEMBL28437808 0.98 CYP1A2 (0.58) CYP1A2CYP2C19CES2CYP2D6PKM
Hydrochloric Acid SCHEMBL717267 0.98 CYP1A2 (0.58) CYP1A2CYP2C19CES2CYP2D6PKM
SCHEMBL169141 0.86 HTR3E (0.50) CYP1A2CYP2C19CES2PKMMEN1
SCHEMBL10140894 0.86 HTR3E (0.50) CYP1A2CYP2C19CES2PKMMEN1
SCHEMBL10140895 0.86 HTR3E (0.50) CYP1A2CYP2C19CES2PKMMEN1
Hydrochloric Acid SCHEMBL717668 0.84 HTR3E (0.49) CYP1A2CYP2C19CES2PKMMEN1
Hydrochloric Acid SCHEMBL717776 0.84 HTR3E (0.49) CYP1A2CYP2C19CES2PKMMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4493546-B1 IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2026-05-06 — — EP disclosed
EP-4493546-A1 IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2025-01-22 — — EP disclosed
US-12030856-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2024-07-09 — — US disclosed
US-11945811-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2024-04-02 — — US disclosed
CN-117561247-A Novel potassium channel inhibitors 阿塞西翁制药公司 2024-02-13 — — CN disclosed
EP-4313973-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Acesion Pharma ApS (DK) 2024-02-07 — — EP disclosed
US-20230406845-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2023-12-21 — — US disclosed
US-20230399301-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2023-12-14 — — US disclosed
US-20230399301-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2023-12-14 — — US disclosed
US-20230399301-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2023-12-14 — — US disclosed
EP-3668841-A1 SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS Acesion Pharma ApS (DK) 2020-06-24 — — EP disclosed
WO-2019034603-A1 SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2019-02-21 — — WO disclosed
EP-2408754-B1 TRIAZOLE DERIVATIVES AS INHIBITORS OF THE VASOPRESSIN RECEPTOR FOR THE TREATMENT OF CARDIAC INSUFFICIENCY BAYER IP GMBH (DE) 2013-10-09 — — EP disclosed
EP-2408754-B1 TRIAZOLE DERIVATIVES AS INHIBITORS OF THE VASOPRESSIN RECEPTOR FOR THE TREATMENT OF CARDIAC INSUFFICIENCY BAYER IP GMBH (DE) 2013-10-09 — — EP disclosed
CN-102438990-A Substituted 2-acetamido-5-aryl-1, 2, 4-triazolones and use thereof BAYER SCHERING PHARMA AG 2012-05-02 — — CN disclosed
CN-102369190-A Triazole derivatives as vasopressin-receptor inhibitors for treating cardiac insufficiency BAYER SCHERING PHARMA AG 2012-03-07 — — CN disclosed
US-20120053218-A1 TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-03-01 — — US disclosed
US-20120053218-A1 TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-03-01 — — US disclosed
US-20120053218-A1 TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-03-01 — — US disclosed
WO-2010105750-A1 TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030856-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 CYP1A2 2222/4885CYP2C19 1480/4885CES2 3760/4885
US-11945811-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 CYP1A2 2222/4885CYP2C19 1480/4885CES2 3760/4885
US-20120053218-A1 TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY AVPR2, AVPR1B, AVPR1A CYP1A2 3005/4885CYP2C19 1958/4885CES2 3566/4885
US-20230406845-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 CYP1A2 2628/4885CYP2C19 1628/4885CES2 3787/4885
US-20230399301-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 CYP1A2 2628/4885CYP2C19 1628/4885CES2 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.